RedHill Biopharma: Rises after safety panel allows COVID-19 treatment study to continue
27/08/2020 12:48
** U.S.-listed shares of Israel-based drug developer
RDHL.O rise 12.7% to $8.5 in premarket trade
** Co says an independent Safety Monitoring Committee has
recommended that its U.S. mid-stage study testing experimental
cancer drug, opaganib, in patients hospitalized with severe
COVID-19 pneumonia continue without changes urn:newsml:reuters.com:*:nGNE1tcqjL
** Co says study has enrolled 50% patients and is expected
to be completed in the coming weeks; Study expects to enroll up
to 270 patients
** RDHL's global mid-stage COVID-19 study also receives
approval in Italy; the study has been approved in the UK, Russia
and Mexico
** Says potential submission of global emergency use
applications as early as Q4
** Up to Wednesday's close, stock had risen 23.4% YTD
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3463;))